

Supporting information for: Folate Receptor
Targeted Theranostic Nanoconstruct for Surface-
Enhanced Raman Scattering (SERS) Imaging and
Photodynamic Therapy (PDT)

Andrew M. Fales,^{†,‡,&,#} Bridget M. Crawford,^{†,‡,&} Tuan Vo-Dinh^{†,‡,§,}*

Fitzpatrick Institute for Photonics, Department of Biomedical Engineering, and Department of
Chemistry, Duke University, 101 Science Drive, Box 90281, Durham, North Carolina 27708,
United States

* Phone: (919) 660-8520, Fax: (919) 613-9145, Email: tuan.vodinh@duke.edu

† Fitzpatrick Institute for Photonics

‡ Department of Biomedical Engineering

§ Department of Chemistry

& These authors contributed equally to this work.

Current affiliation: Center for Devices and Radiological Health, U.S. Food and Drug
Administration, 10903 New Hampshire Ave, Building 62, Room G205C, Silver Spring, MD
20993; andrew.fales@fda.hhs.gov




Figure S1. Calibration curve for the quantitation of PpIX encapsulated in the theranostic nanoparticles. Of the initial 1 µM PpIX, there was found to be 0.67 ± 0.03 µM remaining in the supernatant after silica coating. This results in an estimated 0.33 ± 0.03 µM loaded on 0.1 nM of particles.




Figure S2. Calibration curve for the quantitation of FA-PEG conjugated to the theranostic nanoparticles. After the conjugation reaction, the particles were spun down by centrifugation, the supernatant was collected, diluted 10x, and measured on a UV/Vis spectrophotometer. The FA absorption at 268 nm was used to quantify the remaining FA-PEG in the supernatant. Of the initial 58.8 μM FA-PEG, $52.8 \pm 0.2 \mu\text{M}$ remained in the supernatant after conjugation. This corresponds to $0.204 \pm 0.007 \text{ mg}$ of the initial 2 mg incorporated onto the particles.




Figure S3. Raman mapping of the three different cell lines after 4 hr incubation with untargeted theranostic nanoparticles at 0.1 nM concentration. The sample was scanned in a grid pattern with 20 μm step size, taking a 1 s acquisition at each point. The Raman peak intensity at each point was then integrated to create the false-color map that is overlaid on the brightfield image. All cell lines show little to no Raman signal, indicating that cellular uptake of untargeted nanoparticles is minimal over the 4 hr incubation period.




Figure S4. Resazurin-based cell viability assay of the three cell lines after 4 hr incubation with the theranostic nanoparticles. There is a slight decrease in viability observed after particle incubation, though none are statistically significant.